Why Dupixent Keeps Regeneron A Top Big Pharma Pick [Seeking Alpha]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Seeking Alpha
Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.25 billion. Moreover, on February 19, Regeneron reported that the FDA had accepted the BLA for garetosmab for the treatment of people with a rare genetic disorder called progressive fibrodysplasia ossificans. In this article, you will know why, in my view, Regeneron Pharmaceuticals is still one of the best choices among Big Pharma for long-term-oriented investors. Handsome Bob/E+ via Getty Images Shares of Regeneron Pharmaceuticals ( REGN ), my favorite on the monoclonal antibodies market, have risen 11.5% since the article "Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?" And, of course, the first and primary reason behind this This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- 2 Biotech Giants to Buy in 2026 [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]Yahoo! Finance
- These 5 New York companies are among America's best employers [USA TODAY]USA TODAY
- Regeneron Pharmaceuticals (REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a "sector perform" rating on the stock.MarketBeat
- Regeneron's Dupixent Win And Rare Disease Push Reshape Risk Reward Profile [Yahoo! Finance]Yahoo! Finance
REGN
Earnings
- 1/30/26 - Beat
REGN
Sec Filings
- 3/3/26 - Form 4
- 2/23/26 - Form 4
- 2/19/26 - Form 144
- REGN's page on the SEC website